与 «DYSKINESIA»相关的英语书籍
在以下的参考文献中发现
dyskinesia的用法。与
dyskinesia相关的书籍以及同一来源的简短摘要提供其在 英语文献中的使用情境。
1
Tardive
Dyskinesia: A Task Force Report of the American ...
This book summarizes the progress made over the last decade in understanding the differential diagnosis and epidemiology of tardive dyskinesia, as well as risk factors, course, and treatment.
American Psychiatric Association. Task Force on Tardive Dyskinesia, 1992
2
Pathophysiology, Pharmacology and Biochemistry of
Dyskinesia
This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia.
Jonathan Brotchie, Alireza Minagar, Erwan Bezard, 2011
3
Tardive
Dyskinesia: New Insights for the Healthcare ...
Tardive Dyskinesia: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Tardive Dyskinesia in a compact format.
4
Manual of Clinical Psychopharmacology
about one-quarter first manifest dyskinesia when the antipsychotic is tapered or
stopped (covert dyskinesia). Dyskinesia fades away in some patients when their
antipsychotics are stopped or weeks, months, or years later. Some pa- tients lose
...
Alan F. Schatzberg, Jonathan O. Cole, Charles DeBattista, 2010
5
Association Between Tardive
Dyskinesia and Dopamine Receptor ...
88. Lacro JP JD. The role of ethnicity in the development of tardive dyskinesia.
New York (NY): Cambridge University Press, 1997. 89. Olivera AA, Kiefer MW,
Manley NK. Tardive dyskinesia in psychiatric patients with substance use
disorders.
6
Striatal 5-HT1A Receptor Stimulation Reduces D1 ...
Convergent evidence suggests that serotonin 5-HT1A receptor (5-HT1AR) agonists reduce L-DOPA-induced dyskinesia by auto-regulating aberrant release of L-DOPA-derived dopamine (DA) from raphestriatal neurons.
Kristin Briana Dupre, 2008
tinal motor dysfunctions, and allegedly nicotine,351 inasmuch as the incidence of
tardive dyskinesia is higher among smokers. However, because smoking
induces the activity of the hepatic microsomal enzymes and enhances the
metabolism ...
Ronald F. Pfeiffer, Zbigniew K. Wszolek, Manuchair Ebadi, 2004
8
The Role of Neuroinflammation in L-DOPA-induced
Dyskinesia
Changes in NFkappaB phosphorylation were not observed. Taken together, the current work suggests that inflammation participates in the expression of LID via the NMDA receptor and that this might be mediated by MAP kinase signaling.
Christopher John Barnum, 2008
9
The Maudsley Prescribing Guidelines
Bhoopathi PS et al. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
Cochrane Database Syst Rev 2006;3:CD000205. 37. Adler LA et al. Vitamin E
treatment for tardive dyskinesia. Br J Psychiatry 1995;167:412. 38. Zhang XY et al
.
David Taylor, Carol Paton, Robert Kerwin, 2007
10
Psychiatric Malpractice: Cases and Comments for Clinicians
commentators consider tardive dyskinesia a major public health problem (7). As
a consequence, it is projected to be a significant source of future malpractice
litigation (8). Tardive dyskinesia is most commonly manifested by choreoathetoid
...
Robert I. Simon, Robert L. Sadoff, 1992
包含词语«DYSKINESIA»的新条目
找出国内和国际出版社所讨论的内容，以及词语
dyskinesia在以下新条目的上下文中是如何使用的。
Air Force vet with Parkinson's shares deep-brain stimulation surgery …
But the medication caused a side effect called dyskinesia. ... was aware that deep brain stimulation was an option to relieve the dyskinesia, but ... «MLive.com, 七月 15»
Insider Selling: Adamas Pharmaceuticals Director Ivan M …
... for a complication of Parkinson's disease (PD) known as levodopa-induced dyskinesia (LID), and is evaluating other potential indications for ... «Dakota Financial News, 七月 15»
Zacks' Jason Napodano Is Not Focused on a Biotech Bubble
If they give themselves too much drug, they may have what's known as dyskinesia, which is an inability to control their movements. If they don't ... «CountingPips, 七月 15»
Advancements in Osmotica's CNS Pipeline for Spasticity in MS …
“Osmolex™ ER is a once a day treatment for a highly unmet medical need for Parkinson's disease patients with Dyskinesia; we look forward to ... «Business Wire, 七月 15»
Analysts Set Neurocrine Biosciences PT at $52.12 (NASDAQ:NBIX)
The Company's VMAT2, NBI-98854, is aimed at addressing the unmet medical needs of patients suffering from tardive dyskinesia (TD). «The Legacy, 七月 15»
Reverse is Good for AMARANTUS BIOSCI INC (OTCMKTS:AMBS)
AMBS has licensed Eltoprazine, a Phase 2b-ready small molecule drug indicated for Parkinson's Levodopa induced dyskinesia and adult ... «MicroCap Daily, 七月 15»
Phase IIb Pivotal Clinical Study Of P2B001 For The Treatment Of …
... but long term use of Levodopa is associated with severe side effects over time, that include dyskinesia (uncontrolled involuntary movement) ... «Science 2.0, 七月 15»
Brokerages Set Neurocrine Biosciences Price Target at $52.12 …
The Company's VMAT2, NBI-98854, is aimed at addressing the unmet medical needs of patients suffering from tardive dyskinesia (TD). «Dakota Financial News, 七月 15»
Here's What Teva Pharmaceutical Industries Ltd Is Currently Up To …
... drug candidate, SD-809, which has shown promising results in several indications including Huntington's disease and tardive dyskinesia. «Bidness ETC, 七月 15»
OK to Lower Antipsychotics in Older Schizophrenia Patients
... older age is a risk factor for antipsychotic-induced adverse events including Parkinsonism, tardive dyskinesia, falls, and metabolic syndrome. «MedPage Today, 七月 15»
